nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-205-9-268-275nogr-2065Research ArticleЛЕКЦИЯLECTIONСовременные принципы терапии тяжёлой атаки язвенного колита: от простого к сложномуModern principles of severe ulcerative colitis attack therapy: from simple to complexhttps://orcid.org/0000-0003-2013-8798БарановаТатьяна АлексеевнаBaranovaT. A.tatya-ar@yandex.ruhttps://orcid.org/0000-0001-7250-0977КнязевОлег ВладимировичKnyazevO. V.noemail@neicon.ruhttps://orcid.org/0000-0003-2323-1883ТишаеваИрина АлексеевнаTishaevaI. A.noemail@neicon.ruФГБУ «НМИЦ колопроктологии имени А. Н. Рыжих» Минздрава РоссииРоссияNational Medical Research Center of Coloproctology named after A. N. RyzhikhRussian FederationФГБУ «НМИЦ колопроктологии имени А. Н. Рыжих» Минздрава России; ГБУЗ Московский клинический научно-практический центр имени А. С. Логинова Департамента здравоохранения Москвы; ГБУ Научно-исследовательский институт организации здравоохранения и медицинского менеджмента ДЗМРоссияNational Medical Research Center of Coloproctology named after A. N. Ryzhikh; Loginov Moscow Clinical Scientific Center; Research Institute of Health Organization and Medical ManagementRussian Federation20220710202209268275Copyright © Баранова Т.А., Князев О.В., Тишаева И.А., 20222022Баранова Т.А., Князев О.В., Тишаева И.А.Baranova T.A., Knyazev O.V., Tishaeva I.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/2065

В настоящее время существуют ограниченные общенациональные данные о дозозависимом эффекте и отдаленных результатах терапии глюкокортикостероидами (ГКС) при тяжелых атаках язвенного колита (ЯК). Около 20% пациентов с ЯК имеют хроническое активное заболевание, которое требует назначения нескольких курсов системных ГКС для достижения ремиссии, но при снижении дозы ГКС или вскоре после их отмены случается рецидив ЯК. Нерешенной и спорной научной проблемой остается определение оптимальной продолжительности терапии и дозирования ГКС для достижения ремиссии заболевания и профилактики стероидозависимости и стероидорезистентности при миминизации побочных эффектов от стероидной терапии.

Currently, there are limited national data on the dose-dependent effect and long-term results of glucocorticosteroid (GCS) therapy in severe attacks of ulcerative colitis (UC). Approximately 20% of UC patients have chronic active disease, which requires the appointment of several courses of systemic GCS to achieve remission but with a decrease in the dose of corticosteroids or soon after their cancellation, a relapse of UC occurs. The determination of the optimal duration of therapy and dosing of GCS remains an unresolved and controversial scientific problem to achieve disease remission and prevention of steroid dependence and steroid resistance while minimizing the side effects of steroid therapy.

воспалительные заболевания кишечникаглюкокортикостероидыязвенный колитinflammatory bowel diseaseglucocorticosteroidsulcerative colitisReferencesIvashkin V. T., Shelygin Yu.A., Belousova E. A., et al. Project: clinical guidelines for the diagnostics and treatment of ulcerative colitis. Koloproktologia. 2019;18(4):7-36. (in Russ.) doi:10.33878/2073-7556-2019-18-4-7-36 @@Ивашкин В. Т., Шелыгин Ю. А., Белоусова Е. А., и соавт. Проект клинических рекомендаций по диагностике и лечению язвенного колита. Колопроктология. 2019;18(4):7-36. doi:10.33878/2073-7556-2019-18-4-7-36Ivashkin V. T., Shelygin Yu.A., Belousova E. A., et al. Project: clinical guidelines for the diagnostics and treatment of ulcerative colitis. Koloproktologia. 2019;18(4):7-36. (in Russ.) doi:10.33878/2073-7556-2019-18-4-7-36 @@Ивашкин В. Т., Шелыгин Ю. А., Белоусова Е. А., и соавт. Проект клинических рекомендаций по диагностике и лечению язвенного колита. Колопроктология. 2019;18(4):7-36. doi:10.33878/2073-7556-2019-18-4-7-36Rumyantsev V.G. [Ulcerative colitis: A guide for physicians]. Medical Information Agency Publ. 2009. Moscow. 424 p. (in Russ.) @@Румянцев В. Г. Язвенный колит: Руководство для врачей. ООО «Медицинское информационное агентство». 2009. М.: 424 с.Rumyantsev V.G. [Ulcerative colitis: A guide for physicians]. Medical Information Agency Publ. 2009. Moscow. 424 p. (in Russ.) @@Румянцев В. Г. Язвенный колит: Руководство для врачей. ООО «Медицинское информационное агентство». 2009. М.: 424 с.Seah D., De Cruz P. Review article: the practical management of acute severe ulcerative colitis. Aliment Pharmacol Ther. 2016;43(4):482-513. doi:10.1111/apt.13491;.Seah D., De Cruz P. Review article: the practical management of acute severe ulcerative colitis. Aliment Pharmacol Ther. 2016;43(4):482-513. doi:10.1111/apt.13491;.Hindryckx P., Jairath V., D’Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol. 2016;13(11):654-664. doi:10.1038/nrgastro.2016.116Hindryckx P., Jairath V., D’Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol. 2016;13(11):654-664. doi:10.1038/nrgastro.2016.116Chen J.H., Andrews J. M., Kariyawasam V., et al. Review article: acute severe ulcerative colitis - evidence-based consensus statements. Aliment Pharmacol Ther. 2016;44(2):127-144. doi:10.1111/apt.13670Chen J.H., Andrews J. M., Kariyawasam V., et al. Review article: acute severe ulcerative colitis - evidence-based consensus statements. Aliment Pharmacol Ther. 2016;44(2):127-144. doi:10.1111/apt.13670Becker J. M. Surgical therapy for ulcerative colitis and Crohn’s disease. Gastroenterol Clin North Am. 1999;28(2):371-ix. doi:10.1016/s0889-8553(05)70061-3Becker J. M. Surgical therapy for ulcerative colitis and Crohn’s disease. Gastroenterol Clin North Am. 1999;28(2):371-ix. doi:10.1016/s0889-8553(05)70061-3Carbonnel F., Lavergne A., Lémann M., et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci. 1994;39(7):1550-1557. doi:10.1007/BF02088063Carbonnel F., Lavergne A., Lémann M., et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci. 1994;39(7):1550-1557. doi:10.1007/BF02088063Bansal J., Jenaw R. K., Rao J., Kankaria J., Agrawal N. N. Effectiveness of plain radiography in diagnosing hollow viscus perforation: study of 1,723 patients of perforation peritonitis. Emerg Radiol. 2012;19(2):115-119. doi:10.1007/s10140-011-1007-y;Bansal J., Jenaw R. K., Rao J., Kankaria J., Agrawal N. N. Effectiveness of plain radiography in diagnosing hollow viscus perforation: study of 1,723 patients of perforation peritonitis. Emerg Radiol. 2012;19(2):115-119. doi:10.1007/s10140-011-1007-y;Colombel J. F., Ordás I., Ullman T., et al. Agreement Between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients With Ulcerative Colitis. Gastroenterology. 2016;150(2):389-95.e3. doi:10.1053/j.gastro.2015.10.016Colombel J. F., Ordás I., Ullman T., et al. Agreement Between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients With Ulcerative Colitis. Gastroenterology. 2016;150(2):389-95.e3. doi:10.1053/j.gastro.2015.10.016Kim J.J., Simpson N., Klipfel N., Debose R., Barr N., Laine L. Cytomegalovirus infection in patients with active inflammatory bowel disease. Dig Dis Sci. 2010;55(4):1059-1065. doi:10.1007/s10620-010-1126-4Kim J.J., Simpson N., Klipfel N., Debose R., Barr N., Laine L. Cytomegalovirus infection in patients with active inflammatory bowel disease. Dig Dis Sci. 2010;55(4):1059-1065. doi:10.1007/s10620-010-1126-4Lu N.Z., Wardell S. E., Burnstein K. L., et al.International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol Rev. 2006;58(4):782-797. doi:10.1124/pr.58.4.9Lu N.Z., Wardell S. E., Burnstein K. L., et al.International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol Rev. 2006;58(4):782-797. doi:10.1124/pr.58.4.9Turner D., Kolho K. L., Mack D. R., et al. Glucocorticoid bioactivity does not predict response to steroid therapy in severe pediatric ulcerative colitis. Inflamm Bowel Dis. 2010;16(3):469-473. doi:10.1002/ibd.21070Turner D., Kolho K. L., Mack D. R., et al. Glucocorticoid bioactivity does not predict response to steroid therapy in severe pediatric ulcerative colitis. Inflamm Bowel Dis. 2010;16(3):469-473. doi:10.1002/ibd.21070Dubois-Camacho K., Ottum P. A., Franco-Muñoz D., et al. Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology. World J Gastroenterol. 2017;23(36):6628-6638. doi:10.3748/wjg.v23.i36.6628Dubois-Camacho K., Ottum P. A., Franco-Muñoz D., et al. Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology. World J Gastroenterol. 2017;23(36):6628-6638. doi:10.3748/wjg.v23.i36.6628Daperno M., Sostegni R., Lavagna A., et al. The role of endoscopy in inflammatory bowel disease. Eur Rev Med Pharmacol Sci. 2004;8(5):209-214. PMID: 15638232.Daperno M., Sostegni R., Lavagna A., et al. The role of endoscopy in inflammatory bowel disease. Eur Rev Med Pharmacol Sci. 2004;8(5):209-214. PMID: 15638232.Travis S.P., Farrant J. M., Ricketts C., et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38(6):905-910. doi:10.1136/gut.38.6.905Travis S.P., Farrant J. M., Ricketts C., et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38(6):905-910. doi:10.1136/gut.38.6.905Raddatz D., Middel P., Bockemühl M., et al. Glucocorticoid receptor expression in inflammatory bowel disease: evidence for a mucosal down-regulation in steroid-unresponsive ulcerative colitis. Aliment Pharmacol Ther. 2004;19(1):47-61. doi:10.1046/j.1365-2036.2003.01802.xRaddatz D., Middel P., Bockemühl M., et al. Glucocorticoid receptor expression in inflammatory bowel disease: evidence for a mucosal down-regulation in steroid-unresponsive ulcerative colitis. Aliment Pharmacol Ther. 2004;19(1):47-61. doi:10.1046/j.1365-2036.2003.01802.xDaniel F., Loriot M. A., Seksik P., et al. Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis. Inflamm Bowel Dis. 2007;13(1):19-23. doi:10.1002/ibd.20046Daniel F., Loriot M. A., Seksik P., et al. Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis. Inflamm Bowel Dis. 2007;13(1):19-23. doi:10.1002/ibd.20046Ho G.T., Nimmo E. R., Tenesa A., et al. Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology. 2005;128(2):288-296. doi:10.1053/j.gastro.2004.11.019Ho G.T., Nimmo E. R., Tenesa A., et al. Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology. 2005;128(2):288-296. doi:10.1053/j.gastro.2004.11.019Bantel H., Schmitz M. L., Raible A., Gregor M., Schulze-Osthoff K. Critical role of NF-kappaB and stress-activated protein kinases in steroid unresponsiveness. FASEB J. 2002;16(13):1832-1834. doi:10.1096/fj.02-0223fjeBantel H., Schmitz M. L., Raible A., Gregor M., Schulze-Osthoff K. Critical role of NF-kappaB and stress-activated protein kinases in steroid unresponsiveness. FASEB J. 2002;16(13):1832-1834. doi:10.1096/fj.02-0223fjeSidoroff M., Kolho K. L. Glucocorticoid sensitivity in inflammatory bowel disease. Ann Med. 2012;44(6):578-587. doi:10.3109/07853890.2011.590521Sidoroff M., Kolho K. L. Glucocorticoid sensitivity in inflammatory bowel disease. Ann Med. 2012;44(6):578-587. doi:10.3109/07853890.2011.590521De Iudicibus S., Franca R., Martelossi S., Ventura A., Decorti G. Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease. World J Gastroenterol. 2011;17(9):1095-1108. doi:10.3748/wjg.v17.i9.1095De Iudicibus S., Franca R., Martelossi S., Ventura A., Decorti G. Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease. World J Gastroenterol. 2011;17(9):1095-1108. doi:10.3748/wjg.v17.i9.1095Van Assche G., Sandborn W. J., Feagan B. G., et al. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut. 2006;55(11):1568-1574. doi:10.1136/gut.2005.089854Van Assche G., Sandborn W. J., Feagan B. G., et al. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut. 2006;55(11):1568-1574. doi:10.1136/gut.2005.089854Becker D. E. Basic and clinical pharmacology of glucocorticosteroids. Anesth Prog. 2013;60(1):25-32. doi:10.2344/0003-3006-60.1.25Becker D. E. Basic and clinical pharmacology of glucocorticosteroids. Anesth Prog. 2013;60(1):25-32. doi:10.2344/0003-3006-60.1.25Turner D., Walsh C. M., Steinhart A. H., Griffiths A. M. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5(1):103-110. doi:10.1016/j.cgh.2006.09.033Turner D., Walsh C. M., Steinhart A. H., Griffiths A. M. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5(1):103-110. doi:10.1016/j.cgh.2006.09.033Khalif I. L. Medical tactics at ulcerative colitis.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2006;16(3):58-62. (in Russ.) @@Халиф И. Л. Лечебная тактика при язвенном колите. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2006;16(3):58-62.Khalif I. L. Medical tactics at ulcerative colitis.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2006;16(3):58-62. (in Russ.) @@Халиф И. Л. Лечебная тактика при язвенном колите. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2006;16(3):58-62.D’Haens G. Systematic review: second-generation vs. conventional corticosteroids for induction of remission in ulcerative colitis. Aliment Pharmacol Ther. 2016;44(10):1018-1029. doi:10.1111/apt.13803D’Haens G. Systematic review: second-generation vs. conventional corticosteroids for induction of remission in ulcerative colitis. Aliment Pharmacol Ther. 2016;44(10):1018-1029. doi:10.1111/apt.13803Van Assche G., D’Haens G., Noman M., et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003;125(4):1025-1031. doi:10.1016/s0016-5085(03)01214-9Van Assche G., D’Haens G., Noman M., et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003;125(4):1025-1031. doi:10.1016/s0016-5085(03)01214-9Sjöberg M., Walch A., Meshkat M., et al. Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study. Inflamm Bowel Dis. 2012;18(2):212-218. doi:10.1002/ibd.21680Sjöberg M., Walch A., Meshkat M., et al. Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study. Inflamm Bowel Dis. 2012;18(2):212-218. doi:10.1002/ibd.21680Borren N.Z., Khalili H., Luther J., Colizzo F. P., Garber J. J., Ananthakrishnan A. N. Second-Look Endoscopy in Hospitalized Severe Ulcerative Colitis: A Retrospective Cohort Study. Inflamm Bowel Dis. 2019;25(4):750-755. doi:10.1093/ibd/izy282Borren N.Z., Khalili H., Luther J., Colizzo F. P., Garber J. J., Ananthakrishnan A. N. Second-Look Endoscopy in Hospitalized Severe Ulcerative Colitis: A Retrospective Cohort Study. Inflamm Bowel Dis. 2019;25(4):750-755. doi:10.1093/ibd/izy282Randall J., Singh B., Warren B. F., Travis S. P., Mortensen N. J., George B. D. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Surg. 2010;97(3):404-409. doi:10.1002/bjs.6874Randall J., Singh B., Warren B. F., Travis S. P., Mortensen N. J., George B. D. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Surg. 2010;97(3):404-409. doi:10.1002/bjs.6874Lindgren S.C., Flood L. M., Kilander A. F., Löfberg R., Persson T. B., Sjödahl R. I. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol. 1998;10(10):831-835. doi:10.1097/00042737-199810000-00003Lindgren S.C., Flood L. M., Kilander A. F., Löfberg R., Persson T. B., Sjödahl R. I. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol. 1998;10(10):831-835. doi:10.1097/00042737-199810000-00003Jakobovits S.L., Travis S. P. Management of acute severe colitis. Br Med Bull. 2006;75-76:131-144. Published 2006 Jul 17. doi:10.1093/bmb/ldl001Jakobovits S.L., Travis S. P. Management of acute severe colitis. Br Med Bull. 2006;75-76:131-144. Published 2006 Jul 17. doi:10.1093/bmb/ldl001Baron J.H., Connell A. M., Kanaghinis T. G., Lennard-Jones J.E., Jones A. F. Out-patient treatment of ulcerative colitis.Comparison between three doses of oral prednisone. Br Med J. 1962;2(5302):441-443. doi:10.1136/bmj.2.5302.441Baron J.H., Connell A. M., Kanaghinis T. G., Lennard-Jones J.E., Jones A. F. Out-patient treatment of ulcerative colitis.Comparison between three doses of oral prednisone. Br Med J. 1962;2(5302):441-443. doi:10.1136/bmj.2.5302.441Karpukhin O. Yu. Optimizatsiya metodov diagnostiki i kompleksnogo lecheniya bol’nykh nespetsificheskim yazvennym kolitom [Optimization of diagnostic methods and complex treatment of patients with nonspecific ulcerative colitis]. diss. Doc. of Medical Sciences, 2002. Kazan. @@Карпухин О. Ю., Оптимизация методов диагностики и комплексного лечения больных неспецифическим язвенным колитом. Автореф.дисс. докт.мед.наук., 2002. Казань.Karpukhin O. Yu. Optimizatsiya metodov diagnostiki i kompleksnogo lecheniya bol’nykh nespetsificheskim yazvennym kolitom [Optimization of diagnostic methods and complex treatment of patients with nonspecific ulcerative colitis]. diss. Doc. of Medical Sciences, 2002. Kazan. @@Карпухин О. Ю., Оптимизация методов диагностики и комплексного лечения больных неспецифическим язвенным колитом. Автореф.дисс. докт.мед.наук., 2002. Казань.D’Haens G., Sandborn W. J., Feagan B. G., et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132(2):763-786. doi:10.1053/j.gastro.2006.12.038D’Haens G., Sandborn W. J., Feagan B. G., et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132(2):763-786. doi:10.1053/j.gastro.2006.12.038Järnerot G., Hertervig E., Friis-Liby I., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128(7):1805-1811. doi:10.1053/j.gastro.2005.03.003Järnerot G., Hertervig E., Friis-Liby I., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128(7):1805-1811. doi:10.1053/j.gastro.2005.03.003Lawson M.M., Thomas A. G., Akobeng A. K. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(3): CD005112. Published 2006 Jul 19. doi:10.1002/14651858.CD005112.pub2Lawson M.M., Thomas A. G., Akobeng A. K. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(3): CD005112. Published 2006 Jul 19. doi:10.1002/14651858.CD005112.pub2Lees C.W., Heys D., Ho G. T., et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2007;26(3):411-419. doi:10.1111/j.1365-2036.2007.03383.xLees C.W., Heys D., Ho G. T., et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2007;26(3):411-419. doi:10.1111/j.1365-2036.2007.03383.xWu D., Yang Z., Zhao C., Yao L. Infliximab versus cyclosporine for severe ulcerative colitis refractory to steroids: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2018;97(41): e12657. doi:10.1097/MD.0000000000012657Wu D., Yang Z., Zhao C., Yao L. Infliximab versus cyclosporine for severe ulcerative colitis refractory to steroids: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2018;97(41): e12657. doi:10.1097/MD.0000000000012657Jentzer A., Veyrard P., Roblin X., et al. Cytomegalovirus and Inflammatory Bowel Diseases (IBD) with a Special Focus on the Link with Ulcerative Colitis (UC). Microorganisms. 2020;8(7):1078. Published 2020 Jul 20. doi:10.3390/microorganisms8071078Jentzer A., Veyrard P., Roblin X., et al. Cytomegalovirus and Inflammatory Bowel Diseases (IBD) with a Special Focus on the Link with Ulcerative Colitis (UC). Microorganisms. 2020;8(7):1078. Published 2020 Jul 20. doi:10.3390/microorganisms8071078Ahmed I., Kassem W., Salam Y., Furnari M., Mehta T. Outcome of Cytomegalovirus Colitis in Inflammatory Bowel Disease with Different Regimes of Ganciclovir. Middle East J Dig Dis. 2018;10(4):220-229. doi:10.15171/mejdd.2018.114Ahmed I., Kassem W., Salam Y., Furnari M., Mehta T. Outcome of Cytomegalovirus Colitis in Inflammatory Bowel Disease with Different Regimes of Ganciclovir. Middle East J Dig Dis. 2018;10(4):220-229. doi:10.15171/mejdd.2018.114Parragi L., Fournier N., Zeitz J., et al. Colectomy Rates in Ulcerative Colitis are Low and Decreasing: 10-year Follow-up Data From the Swiss IBD Cohort Study. J Crohns Colitis. 2018;12(7):811-818. doi:10.1093/ecco-jcc/jjy040Parragi L., Fournier N., Zeitz J., et al. Colectomy Rates in Ulcerative Colitis are Low and Decreasing: 10-year Follow-up Data From the Swiss IBD Cohort Study. J Crohns Colitis. 2018;12(7):811-818. doi:10.1093/ecco-jcc/jjy040

The authors declare that there are no conflicts of interest present.